Arbutus Biopharma Corp Income (Loss) from Equity Method Investments
Arbutus Biopharma Corp (ABUS) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-03-03
- Arbutus Biopharma Corp income (loss) from equity method investments for the quarter ending 2021-12-31 was $0.00.
- Arbutus Biopharma Corp income (loss) from equity method investments for the quarter ending 2021-09-30 was $0.00.
- Arbutus Biopharma Corp income (loss) from equity method investments for the quarter ending 2020-12-31 was $0.00.
- Arbutus Biopharma Corp income (loss) from equity method investments for the quarter ending 2020-09-30 was -$2.54M.
- Arbutus Biopharma Corp income (loss) from equity method investments for fiscal 2021 was $0.00.
- Arbutus Biopharma Corp income (loss) from equity method investments for fiscal 2020 was -$2.54M.
- Arbutus Biopharma Corp income (loss) from equity method investments for fiscal 2019 was -$22.52M.
- Arbutus Biopharma Corp income (loss) from equity method investments for fiscal 2018 was -$5.56M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$2.54M derived: sum of 2 quarters · filed 2022-03-03 | -$2.54M derived: sum of 3 quarters · filed 2022-03-03 | -$2.54M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$2.54M 10-Q · filed 2021-11-04 | -$2.54M derived: sum of 2 quarters · filed 2021-11-04 | -$2.54M 10-Q · filed 2021-11-04 | -$13.57M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | -$11.03M derived: sum of 3 quarters · filed 2021-03-04 | -$14.54M derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | -$11.03M derived: sum of 2 quarters · filed 2021-03-04 | -$14.54M derived: sum of 3 quarters · filed 2021-03-04 | -$17.87M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-12-31 | -$11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$14.54M derived: sum of 2 quarters · filed 2021-03-04 | -$17.87M derived: sum of 3 quarters · filed 2021-03-04 | -$22.52M 10-K · filed 2021-03-04 |
| 2019-09-30 | -$3.51M 10-Q · filed 2020-11-05 | -$6.85M derived: sum of 2 quarters · filed 2020-11-05 | -$11.50M 10-Q · filed 2020-11-05 | -$14.22M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$3.33M 10-Q · filed 2020-08-07 | -$7.99M 10-Q · filed 2020-08-07 | -$10.71M derived: sum of 3 quarters · filed 2020-08-07 | -$13.55M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$4.65M 10-Q · filed 2020-05-11 | -$7.38M derived: sum of 2 quarters · filed 2020-05-11 | -$10.21M derived: sum of 3 quarters · filed 2020-05-11 | -$10.21M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$5.56M derived: sum of 2 quarters · filed 2019-11-06 | -$5.56M derived: sum of 3 quarters · filed 2019-11-06 | -$5.56M 10-K · filed 2019-03-07 |
| 2018-09-30 | -$2.84M 10-Q · filed 2019-11-06 | -$2.84M derived: sum of 2 quarters · filed 2019-11-06 | -$2.84M 10-Q · filed 2019-11-06 | -$2.84M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | $0.00 derived: sum of 3 quarters · filed 2019-08-05 | $0.00 derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-06 | $0.00 derived: sum of 2 quarters · filed 2019-05-06 | $0.00 derived: sum of 3 quarters · filed 2019-05-06 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |